Related Experiment Videos
Gene therapy for restenosis: current status
Juha Rutanen1, Johanna Markkanen, Seppo Ylä-Herttuala
1A. I. Virtanen Institute, University of Kuopio, Kuopio, Finland.
Abstract:
Atherosclerosis is a major cause of morbidity and mortality in Western world. Vascular occlusion caused by atherosclerosis usually requires invasive treatment, such as surgical bypass or angioplasty. However, bypass graft failure and restenosis limit the usefulness of these procedures, with 20% of patients needing a new revascularisation procedure within 6 months of angioplasty. Numerous pharmacological agents have been investigated for the prevention of restenosis but none has shown undisputed efficacy in clinical medicine. Gene transfer offers a novel approach to the treatment of restenosis because of easy accessibility of vessels and already existing gene delivery methods. It can be used to overexpress therapeutically important proteins locally without high systemic toxicity, and the therapeutic effect can be targeted to a particular pathophysiological event. Promising results have been obtained from many pre-clinical experiments using therapeutic genes or oligonucleotides to prevent restenosis. Early clinical trials have shown that plasmid- and adenovirus-mediated vascular gene transfers can be conducted safely and are well tolerated. Ex vivo gene therapy with E2F-decoy succeeded in reducing graft occlusion rate after surgical bypass in a randomised, double-blind clinical trial. In the future, further development of gene delivery methods and vectors is needed to improve the efficacy and safety of gene therapy. Also, better knowledge of vascular biology at the molecular level is needed to find optimal strategies and gene combinations to treat restenosis. Provided that these difficulties can be solved, gene therapy offers an enormous potential for clinical medicine in the future.
Insights
Gene therapy offers a promising new approach to prevent restenosis after vascular procedures. Early trials show safety and potential, with ongoing research to improve efficacy for future clinical applications.
Area of Science:
- Cardiovascular Medicine
- Molecular Biology
- Regenerative Medicine
Background:
- Atherosclerosis is a leading cause of death, often necessitating invasive vascular treatments like bypass or angioplasty.
- Bypass graft failure and restenosis significantly limit the long-term success of these interventions, with high revascularization rates.
- Current pharmacological treatments for restenosis lack undisputed clinical efficacy.
Purpose of the Study:
- To explore gene transfer as a novel therapeutic strategy for preventing vascular restenosis.
- To evaluate the potential of local gene overexpression to mitigate restenosis without systemic toxicity.
- To review pre-clinical and early clinical findings on gene therapy for vascular applications.
Main Methods:
- Investigation of gene transfer methods for local protein overexpression in vascular tissues.
- Review of pre-clinical studies utilizing therapeutic genes and oligonucleotides.
- Analysis of early clinical trials assessing plasmid- and adenovirus-mediated gene transfer safety and tolerability.
- Examination of ex vivo gene therapy, specifically E2F-decoy, in a randomized trial for surgical bypass graft occlusion.
Main Results:
- Pre-clinical experiments demonstrate promising results using genes and oligonucleotides to prevent restenosis.
- Early clinical trials indicate that vascular gene transfer is safe and well-tolerated.
- Ex vivo gene therapy with E2F-decoy successfully reduced graft occlusion rates in a clinical trial.
Conclusions:
- Gene therapy presents a novel and potentially effective approach to treating vascular restenosis.
- Further advancements in gene delivery methods and vectors are crucial for enhancing efficacy and safety.
- A deeper understanding of molecular vascular biology is essential for developing optimal gene therapy strategies for restenosis.